Equities

ImmuPharma PLC

IMM:LSE

ImmuPharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.06
  • Today's Change0.015 / 0.74%
  • Shares traded312.49k
  • 1 Year change-33.60%
  • Beta2.4849
Data delayed at least 20 minutes, as of May 03 2024 12:13 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year ImmuPharma PLC had revenues fall -100.00% from 118.35k to 0.00, though the company grew net income from a loss of 8.17m to a smaller loss of 3.81m.
Gross margin--
Net profit margin-4,275.31%
Operating margin-3,799.10%
Return on assets-97.05%
Return on equity-159.35%
Return on investment-159.35%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at ImmuPharma PLC fell by 981.56k. Cash Flow from Financing totalled 1.55m or -- of revenues. In addition the company used 2.35m for operations while cash used for investing totalled 77.42k.
Cash flow per share-0.0087
Price/Cash flow per share--
Book value per share0.0052
Tangible book value per share0.0038
More ▼

Balance sheet in GBPView more

ImmuPharma PLC uses little or no debt in its capital structure.
Current ratio1.17
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.